These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 2283998)

  • 1. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.
    Namba H; Rubin SA; Fagin JA
    Mol Endocrinol; 1990 Oct; 4(10):1474-9. PubMed ID: 2283998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues.
    Capella G; Matias-Guiu X; Ampudia X; de Leiva A; Perucho M; Prat J
    Diagn Mol Pathol; 1996 Mar; 5(1):45-52. PubMed ID: 8919545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.
    Liu RT; Hou CY; You HL; Huang CC; Hock-Liew ; Chou FF; Wang PW; Cheng JT
    Thyroid; 2004 Aug; 14(8):616-21. PubMed ID: 15320975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H-ras protooncogene mutations in human thyroid neoplasms.
    Namba H; Gutman RA; Matsuo K; Alvarez A; Fagin JA
    J Clin Endocrinol Metab; 1990 Jul; 71(1):223-9. PubMed ID: 2196280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras oncogene mutations in benign and malignant thyroid neoplasms.
    Karga H; Lee JK; Vickery AL; Thor A; Gaz RD; Jameson JL
    J Clin Endocrinol Metab; 1991 Oct; 73(4):832-6. PubMed ID: 1890154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of activating ras mutations in morphologically characterized thyroid nodules.
    Ezzat S; Zheng L; Kolenda J; Safarian A; Freeman JL; Asa SL
    Thyroid; 1996 Oct; 6(5):409-16. PubMed ID: 8936664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
    Shi YF; Zou MJ; Schmidt H; Juhasz F; Stensky V; Robb D; Farid NR
    Cancer Res; 1991 May; 51(10):2690-3. PubMed ID: 2021946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers.
    Bouras M; Bertholon J; Dutrieux-Berger N; Parvaz P; Paulin C; Revol A
    Eur J Endocrinol; 1998 Aug; 139(2):209-16. PubMed ID: 9724079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Ras mutations in thyroid neoplasia.
    Esapa CT; Johnson SJ; Kendall-Taylor P; Lennard TW; Harris PE
    Clin Endocrinol (Oxf); 1999 Apr; 50(4):529-35. PubMed ID: 10468914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-ras mutation of thyroid tumor with special reference to the follicular type.
    Oyama T; Suzuki T; Hara F; Iino Y; Ishida T; Sakamoto A; Nakajima T
    Pathol Int; 1995 Jan; 45(1):45-50. PubMed ID: 7704243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point mutations of ras and Gs alpha subunit genes in thyroid tumors.
    Horie H; Yokogoshi Y; Tsuyuguchi M; Saito S
    Jpn J Cancer Res; 1995 Aug; 86(8):737-42. PubMed ID: 7559096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-ras 61 oncogene mutations in Hürthle cell tumors.
    Schark C; Fulton N; Jacoby RF; Westbrook CA; Straus FH; Kaplan EL
    Surgery; 1990 Dec; 108(6):994-9; discussion 999-1000. PubMed ID: 2247846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of mutations in all three ras genes in human thyroid tumors.
    Suarez HG; du Villard JA; Severino M; Caillou B; Schlumberger M; Tubiana M; Parmentier C; Monier R
    Oncogene; 1990 Apr; 5(4):565-70. PubMed ID: 2183158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
    Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
    Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.
    Bouras M; Parvaz P; Berger N; Paulin C; Revol A
    Ann Biol Clin (Paris); 1995; 53(10-11):549-55. PubMed ID: 8787281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant deoxyribonucleic acid methylation in human thyroid tumors.
    Matsuo K; Tang SH; Zeki K; Gutman RA; Fagin JA
    J Clin Endocrinol Metab; 1993 Oct; 77(4):991-5. PubMed ID: 7691865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in ras oncogenes: rare events in ultraviolet B radiation-induced mouse skin tumorigenesis.
    Khan SG; Mohan RR; Katiyar SK; Wood GS; Bickers DR; Mukhtar H; Agarwal R
    Mol Carcinog; 1996 Feb; 15(2):96-103. PubMed ID: 8599584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
    Cyniak-Magierska A; Brzeziańska E; Januszkiewicz-Caulier J; Jarzab B; Lewiński A
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):594-9. PubMed ID: 17943694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas.
    Manenti G; Pilotti S; Re FC; Della Porta G; Pierotti MA
    Eur J Cancer; 1994; 30A(7):987-93. PubMed ID: 7946598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.